DMII
$9.96
Market ClosedAs of Mar 17, 8:00 PM UTC
Drugs Made In America Acquisition II Corp.
Historical Price
Price (Line)
Synthesizing Whystock Narrative...
Loading Financials...
Peer Comparison
JPMBACGS
Whystock Valuation Model
Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$9.96
Potential Upside
5%
Whystock Fair Value$10.46
Price
UndervaluedFair ValueOvervalued
Fundamentals
Drugs Made In America Acquisition II Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combination with one or mor...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$653.13M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
-
Quick Ratio
Tight liquidity. Monitor cash flow carefully against debt.
0.07
Recent News
NexGen Energy’s Rook I Project Emerges as a Key Source in the Next Uranium Supply Wave
MMCAP International increased its stake in NexGen Energy during the fourth quarter, deepening exposure to the company’s Rook I uranium project in Canada. As governments extend reactor lifespans and reconsider nuclear expansion, attention is turning to future uranium supply and how quickly projects like Rook I can begin production.
Drugs Made In America Acquisition II Corp. (NASDAQ:DMII) is largely controlled by institutional shareholders who own 79% of the company
Key Insights Institutions' substantial holdings in Drugs Made In America Acquisition II implies that they have...